US Hereditary Angioedema Therapeutics Market Summary

As per Market Research Future analysis, the US hereditary angioedema-therapeutics market size was estimated at 1761.4 USD Million in 2024. The US hereditary angioedema-therapeutics market is projected to grow from 1833.62 USD Million in 2025 to 2739.7 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 4% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The US hereditary angioedema-therapeutics market is experiencing a transformative shift towards innovative treatment options and increased patient engagement.

The emergence of targeted therapies is reshaping treatment paradigms in the hereditary angioedema market.
Increased patient awareness and education are driving demand for effective therapeutic solutions.
Regulatory and reimbursement developments are facilitating market access for new therapies.
The rising incidence of hereditary angioedema and advancements in biotechnology are key drivers of market growth.

Market Size & Forecast

2024 Market Size	1761.4 (USD Million)
2035 Market Size	2739.7 (USD Million)
CAGR (2025 - 2035)	4.1%

Major Players

Takeda Pharmaceutical Company Limited (JP), CSL Behring (US), Shire (US), Pharming Group N.V. (NL), BioCryst Pharmaceuticals, Inc. (US), Sobi (SE), Ferring Pharmaceuticals (CH), Grifols S.A. (ES)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

US Hereditary Angioedema Therapeutics Market Trends

The hereditary angioedema-therapeutics market is currently experiencing notable developments. These are driven by advancements in treatment options and increased awareness of the condition. Hereditary angioedema, characterized by recurrent episodes of severe swelling, has historically been underdiagnosed and undertreated. However, recent efforts to educate healthcare professionals and patients about the disease have led to improved diagnosis rates. This shift is likely to enhance the demand for effective therapeutics, as patients seek reliable solutions to manage their symptoms. Furthermore, the introduction of novel therapies, including targeted biologics, appears to be reshaping treatment paradigms, offering patients more tailored options. In addition to the advancements in therapeutics, the hereditary angioedema-therapeutics market is also influenced by regulatory changes and reimbursement policies. The evolving landscape of healthcare regulations may facilitate faster approvals for new treatments, thereby accelerating their availability to patients. Moreover, favorable reimbursement frameworks could enhance patient access to these therapies, potentially driving market growth. As the understanding of hereditary angioedema continues to evolve, stakeholders in the market are likely to adapt their strategies to align with emerging trends and patient needs, ensuring that the therapeutic landscape remains dynamic and responsive to the challenges posed by this condition.

Emergence of Targeted Therapies

The hereditary angioedema-therapeutics market is witnessing a shift towards targeted therapies that specifically address the underlying mechanisms of the condition. These innovative treatments aim to provide more effective symptom management and reduce the frequency of attacks. As research progresses, the development of biologics and other advanced therapies is likely to enhance patient outcomes and satisfaction.

Increased Patient Awareness and Education

There is a growing emphasis on patient education and awareness regarding hereditary angioedema. Initiatives aimed at informing both patients and healthcare providers about the condition are becoming more prevalent. This trend is expected to lead to earlier diagnosis and treatment, ultimately improving the quality of life for those affected.

Regulatory and Reimbursement Developments

Recent changes in regulatory frameworks and reimbursement policies are shaping the hereditary angioedema-therapeutics market. Streamlined approval processes for new therapies may facilitate quicker access for patients. Additionally, favorable reimbursement conditions could enhance affordability and accessibility, encouraging more patients to seek treatment.

US Hereditary Angioedema Therapeutics Market Drivers

Advancements in Biotechnology

Technological advancements in biotechnology are significantly influencing the hereditary angioedema-therapeutics market. Innovations in drug development, particularly in biologics and monoclonal antibodies, have led to the creation of targeted therapies that offer improved efficacy and safety profiles. For instance, recent breakthroughs in gene therapy and RNA-based treatments hold promise for long-term management of HAE. The market is projected to witness substantial growth, with estimates indicating a compound annual growth rate (CAGR) of over 15% in the coming years. These advancements not only enhance treatment options but also attract investment from biotech firms, thereby expanding the therapeutic landscape for HAE.

Enhanced Regulatory Frameworks

The regulatory landscape for the hereditary angioedema-therapeutics market is evolving, with enhanced frameworks aimed at expediting the approval of new therapies. Regulatory agencies, such as the FDA, are increasingly adopting streamlined processes for the review of treatments targeting rare diseases. This shift is likely to facilitate faster access to innovative therapies for patients suffering from HAE. Additionally, the introduction of programs like Breakthrough Therapy Designation may encourage pharmaceutical companies to invest in HAE treatments, knowing that they can navigate the approval process more efficiently. As a result, the market may experience a surge in new product launches, ultimately benefiting patients and healthcare providers.

Increased Focus on Personalized Medicine

The shift towards personalized medicine is reshaping the hereditary angioedema-therapeutics market. Tailoring treatments to individual patient profiles enhances therapeutic outcomes and minimizes adverse effects. This trend is particularly relevant in HAE, where genetic variations can influence treatment response. As healthcare providers increasingly adopt personalized approaches, the demand for diagnostic tools and targeted therapies is expected to rise. The market may see a surge in the development of companion diagnostics that identify suitable candidates for specific therapies. This focus on personalized medicine could potentially lead to a more efficient allocation of healthcare resources, ultimately benefiting patients and healthcare systems alike.

Rising Incidence of Hereditary Angioedema

The hereditary angioedema-therapeutics market is experiencing growth due to the increasing incidence of HAE in the US. Recent estimates suggest that HAE affects approximately 1 in 10,000 to 1 in 50,000 individuals, leading to a heightened demand for effective therapeutic options. As awareness of the condition grows among healthcare providers and patients, the need for specialized treatments becomes more pronounced. This rising incidence is likely to drive investments in research and development, as pharmaceutical companies seek to address the unmet needs of patients suffering from HAE. Furthermore, the increasing recognition of HAE as a serious health concern may lead to more comprehensive healthcare policies and funding, further bolstering the hereditary angioedema-therapeutics market.

Growing Investment in Rare Disease Research

Investment in research for rare diseases, including hereditary angioedema, is on the rise, positively impacting the hereditary angioedema-therapeutics market. With the increasing recognition of HAE as a rare but serious condition, funding from both public and private sectors is becoming more accessible. Initiatives aimed at fostering innovation in rare disease therapeutics are likely to accelerate the development of new treatments. In the US, the Orphan Drug Act provides incentives for companies to develop therapies for rare diseases, which may further stimulate market growth. This influx of investment not only supports the development of novel therapies but also enhances patient access to existing treatments.

Market Segment Insights

By Type: Type I (Largest) vs. Type II (Fastest-Growing)

In the US hereditary angioedema-therapeutics market, Type I is the most prevalent segment, commanding a significant share among treatment types. As a well-established classification, Type I therapies have secured a strong foothold due to their effectiveness and widespread recognition within the medical community. Conversely, Type II is emerging rapidly, appealing to a niche yet growing patient demographic, as ongoing research and development efforts bolster its visibility and acceptance. Growth trends in this segment are largely driven by advances in biotechnology, with innovative therapies emerging that cater specifically to the needs of Type II patients. Increased awareness of hereditary angioedema and improved diagnostic capabilities are also contributing factors. As a result, Type II is positioned to experience rapid growth, benefiting from heightened investment in research and a supportive regulatory framework encouraging new therapeutic options.

Type I: Dominant vs. Type II: Emerging

Type I therapies dominate the market due to their established efficacy and broad recognition among healthcare providers. These treatments have been the cornerstone of managing hereditary angioedema for years, allowing for strong patient adherence and satisfaction. On the other hand, Type II therapies are emerging as alternatives that address the specific needs of patients who may not respond as well to Type I treatments. This segment is characterized by ongoing research and innovative therapeutic solutions, aimed at improving management strategies and patient outcomes. As investments in R&D for Type II continue to grow, this segment is expected to gain a more significant market presence, driven by its potential to offer effective alternatives and a robust pipeline of new therapies.

By Drug Class: C1 Esterase Inhibitor (Largest) vs. Selective Bradykinin B2 Receptor Antagonist (Fastest-Growing)

In the US hereditary angioedema-therapeutics market, the market share is notably dominated by C1 Esterase Inhibitor, which has established itself as the leading drug class due to its efficacy in managing acute attacks. Selective Bradykinin B2 Receptor Antagonist follows as a significant player, demonstrating a growing interest from healthcare providers and patients alike. Kallikrein Inhibitor and Others contribute to the market but occupy smaller shares, making C1 Esterase Inhibitor and Selective Bradykinin B2 Receptor Antagonist the focus of this segment. The growth trends for these drug classes are influenced by a combination of factors including an increasing awareness of hereditary angioedema, advancements in drug development, and a rising patient population seeking effective treatment. There is a substantial emphasis on innovative therapies, particularly for Selective Bradykinin B2 Receptor Antagonist, which is gaining momentum as clinicians recognize its potential benefits over traditional treatments. The competitive landscape continues to evolve, fostering an environment conducive to research and development efforts aimed at enhancing treatment options for patients.

C1 Esterase Inhibitor (Dominant) vs. Selective Bradykinin B2 Receptor Antagonist (Emerging)

C1 Esterase Inhibitor continues to hold a dominant position in the US hereditary angioedema-therapeutics market, recognized for its ability to rapidly alleviate symptoms during an acute attack. This drug class is well-received among practitioners for its established safety profile and effectiveness. On the other hand, Selective Bradykinin B2 Receptor Antagonist is emerging as a crucial alternative, particularly for patients who may not respond optimally to traditional therapies. It offers a new mechanism of action that appeals to both physicians and patients, highlighting the need for innovative solutions tailored to individual needs. The growing adoption of Selective Bradykinin B2 Receptor Antagonist reflects an important shift towards more personalized approaches in treating hereditary angioedema.

By Treatment: Prophylaxis (Largest) vs. On-demand (Fastest-Growing)

In the US hereditary angioedema-therapeutics market, the treatment segment is predominantly driven by prophylaxis, which commands the largest market share. Prophylaxis treatments have established themselves as the cornerstone for managing hereditary angioedema due to their effectiveness in preventing acute attacks. In contrast, on-demand therapies, while currently smaller in market share, are gaining traction as they provide immediate relief and are increasingly recognized for their essential role in acute management. Growth trends within this segment are particularly promising for on-demand therapies, which are categorized as the fastest-growing option due to rising patient awareness and the adaptability of these treatments. Factors such as innovation in drug formulations and enhanced accessibility have contributed to the rise of on-demand therapies. Additionally, the changing landscape of patient needs emphasizes the importance of flexible treatment modalities, boosting the demand for on-demand solutions, while prophylaxis continues to serve as the standard of care.

Prophylaxis (Dominant) vs. On-demand (Emerging)

Prophylaxis treatments are currently dominant in the US hereditary angioedema-therapeutics market, primarily focusing on long-term prevention strategies to reduce the frequency and severity of angioedema attacks. These therapies are often preferred by patients for their consistent effectiveness and reliability, leading to a robust market presence. Conversely, on-demand treatments, while emerging, are crucial for immediate relief during acute attacks, showcasing rapid innovation in delivery mechanisms and formulations. The growing recognition of the importance of personalized patient care is further driving the emergence of on-demand solutions. As healthcare providers increasingly adapt to individualized treatment regimens, both prophylaxis and on-demand therapies are expected to coexist and complement each other in enhancing patient outcomes.

By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

Within the US hereditary angioedema-therapeutics market, the route of administration segment is characterized by three prominent values: Intravenous, Subcutaneous, and Oral. Intravenous administration holds the largest market share, favored for its rapid onset of action and efficacy in acute treatment scenarios. Conversely, Subcutaneous administration has emerged as the fastest-growing route due to its ease of use, patient preference, and advancements in formulization that allow for self-administration, which is becoming increasingly popular among patients seeking convenience and autonomy. Growth trends for these routes of administration are driven by significant factors such as the rising awareness of hereditary angioedema and the associated treatment options. The demand for patient-friendly formulations has stimulated interest in Subcutaneous options, which promote better adherence and quality of life for patients. In contrast, Intravenous treatments remain critical for acute episodes, reinforcing their importance in the therapeutic landscape. As innovation continues, this segment is expected to evolve, accommodating both efficacy and patient-centric preferences.

Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration is the dominant method in the US hereditary angioedema-therapeutics market, primarily due to its ability to deliver immediate relief during acute angioedema attacks, ensuring rapid therapeutic effects. This method is often preferred in clinical settings where intense monitoring and rapid response are essential. On the other hand, Subcutaneous administration is emerging rapidly, with a focus on convenience and self-management. Patients favor this route as it offers a practical and less invasive alternative, enabling them to manage their conditions effectively at home. The increasing development of easy-to-use devices for self-injection and the reduced need for healthcare provider visits further bolster the appeal of Subcutaneous therapies, positioning them as a significant part of future treatment paradigms.

By Distribution Channel: Hospital Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing)

In the US hereditary angioedema-therapeutics market, the distribution of market share among the different channels reveals that Hospital Pharmacy takes the lead, accounting for a significant portion. Retail Pharmacies also play a crucial role, but their share is notably less compared to hospitals. Online Pharmacies are emerging as a notable player, gradually capturing attention and market share in this therapeutics segment. Growth trends in this segment indicate a shift towards Online Pharmacies, which are recognized for their convenience and accessibility, appealing particularly to younger demographics and tech-savvy patients. Hospital Pharmacies continue to dominate due to their established infrastructure and relationships with healthcare providers, while Retail Pharmacies are adapting to the e-commerce trend to maintain competitiveness.

Hospital Pharmacy (Dominant) vs. Online Pharmacy (Emerging)

Hospital Pharmacy remains a dominant force in the US hereditary angioedema-therapeutics market due to its ability to provide specialized care and immediate access to treatments. Hospitals have integrated these therapeutics into their care protocols, ensuring that patients receive timely and effective treatment. Conversely, Online Pharmacies are emerging rapidly, driven by the increasing preference for home delivery and online consultations. They offer advantages such as convenience and often lower prices, making them attractive to patients who seek easy access to their medications. As the market evolves, the competition between these two channels is intensifying, each adapting to meet the changing needs of patients.

Get more detailed insights about US Hereditary Angioedema Therapeutics Market

Request Free Sample

Key Players and Competitive Insights

The hereditary angioedema-therapeutics market is characterized by a dynamic competitive landscape, driven by increasing awareness of the condition and advancements in treatment options. Key players such as Takeda Pharmaceutical Company Limited (Japan), BioCryst Pharmaceuticals, Inc. (US), and CSL Behring (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Takeda focuses on innovation and expanding its product portfolio, while BioCryst emphasizes strategic partnerships to bolster its research capabilities. CSL Behring, on the other hand, is concentrating on regional expansion and optimizing its supply chain to improve accessibility to therapies. Collectively, these strategies contribute to a competitive environment that is increasingly focused on patient-centric solutions and technological advancements.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. The collective influence of these key players shapes the competitive dynamics, as they engage in continuous innovation and strategic collaborations to meet the evolving needs of patients.
In October BioCryst Pharmaceuticals, Inc. (US) announced a collaboration with a leading biotechnology firm to develop next-generation therapies for hereditary angioedema. This partnership is strategically significant as it aims to leverage advanced technologies and expertise, potentially accelerating the development of innovative treatment options. Such collaborations may enhance BioCryst's competitive edge by expanding its research capabilities and diversifying its product pipeline.
In September Takeda Pharmaceutical Company Limited (Japan) launched a new patient support program designed to improve treatment adherence among hereditary angioedema patients. This initiative underscores Takeda's commitment to patient-centric care and reflects a broader trend in the industry towards enhancing patient engagement. By providing comprehensive support, Takeda aims to strengthen its market position and foster long-term relationships with patients and healthcare providers.
In August CSL Behring (US) expanded its manufacturing capabilities in the US to increase the production of its therapies for hereditary angioedema. This strategic move is likely to enhance supply chain reliability and ensure timely access to treatments for patients. By investing in local manufacturing, CSL Behring not only addresses demand but also positions itself favorably in a competitive landscape where supply chain efficiency is paramount.
As of November current trends in the hereditary angioedema-therapeutics market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of delivering high-quality, effective therapies.

Key Companies in the US Hereditary Angioedema Therapeutics Market include

Industry Developments

The US Hereditary Angioedema Therapeutics Market has seen significant developments recently. In June 2023, CSL Behring announced progress in its gene therapy development for hereditary angioedema, showcasing advancements in reducing treatment frequency for patients while enhancing efficacy.

Takeda Pharmaceutical reported elevated market performance due to the successful launch of its new therapies, which have gained traction among healthcare professionals and patients for their improved safety profiles. In terms of mergers and acquisitions, Emergent BioSolutions completed its acquisition of a small biotech firm focused on rare diseases, including hereditary angioedema, in July 2023.

Furthermore, Biocryst Pharmaceuticals achieved a market valuation growth following its innovative product launches; this has solidified its presence in the American market, contributing to an overall market expansion. Over the past two to three years, the market has also seen heightened competition and increased investment in Research and Development as companies such as Amgen and Regeneron Pharmaceuticals emphasize novel therapeutics aimed at improving patient outcomes.

Government support through funding for cutting-edge therapies has further stimulated market activity, promising a robust growth landscape for the industry moving forward.

Future Outlook

US Hereditary Angioedema Therapeutics Market Future Outlook

The Hereditary Angioedema Therapeutics Market is projected to grow at a 4.1% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing patient awareness.

New opportunities lie in:

Development of personalized treatment plans leveraging genetic profiling. Expansion of telehealth services for remote patient monitoring. Investment in educational programs for healthcare providers on HAE management.

By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment accessibility and innovation.

Market Segmentation

US Hereditary Angioedema Therapeutics Market Type Outlook

Type I
Type II

US Hereditary Angioedema Therapeutics Market Treatment Outlook

Prophylaxis
On-demand

US Hereditary Angioedema Therapeutics Market Drug Class Outlook

C1 Esterase Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Kallikrein Inhibitor
Others

US Hereditary Angioedema Therapeutics Market Distribution Channel Outlook

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

US Hereditary Angioedema Therapeutics Market Route of Administration Outlook

Intravenous
Subcutaneous
Oral

Report Scope

MARKET SIZE 2024	1761.4(USD Million)
MARKET SIZE 2025	1833.62(USD Million)
MARKET SIZE 2035	2739.7(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	4.1% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	Takeda Pharmaceutical Company Limited (JP), CSL Behring (US), Shire (US), Pharming Group N.V. (NL), BioCryst Pharmaceuticals, Inc. (US), Sobi (SE), Ferring Pharmaceuticals (CH), Grifols S.A. (ES)
Segments Covered	Type, Drug Class, Treatment, Route of Administration, Distribution Channel
Key Market Opportunities	Advancements in gene therapy and monoclonal antibodies enhance treatment options in the hereditary angioedema-therapeutics market.
Key Market Dynamics	Rising demand for innovative therapies drives competition and regulatory scrutiny in the hereditary angioedema-therapeutics market.
Countries Covered	US

FAQs

What was the market valuation of the US hereditary angioedema-therapeutics market in 2024?

The market valuation was $1761.4 Million in 2024.

What is the projected market valuation for the US hereditary angioedema-therapeutics market by 2035?

The projected valuation for 2035 is $2739.7 Million.

What is the expected CAGR for the US hereditary angioedema-therapeutics market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.1%.

Which drug class had the highest valuation in the US hereditary angioedema-therapeutics market in 2024?

The C1 Esterase Inhibitor drug class had a valuation of $600.0 Million in 2024.

What are the projected valuations for Type I and Type II hereditary angioedema by 2035?

Type I is projected to reach $1600.0 Million, while Type II is expected to reach $1139.7 Million by 2035.

Which route of administration is anticipated to have the highest valuation in the US hereditary angioedema-therapeutics market by 2035?

The subcutaneous route is anticipated to reach $1100.0 Million by 2035.

What distribution channel had the highest valuation in 2024 for the US hereditary angioedema-therapeutics market?

The hospital pharmacy distribution channel had a valuation of $704.56 Million in 2024.

Which key player is associated with the development of therapies for hereditary angioedema?

Takeda Pharmaceutical Company Limited is one of the key players in the development of therapies for hereditary angioedema.

What was the valuation of the on-demand treatment segment in the US hereditary angioedema-therapeutics market in 2024?

The on-demand treatment segment was valued at $761.4 Million in 2024.

What is the projected growth for the Kallikrein Inhibitor drug class by 2035?

The Kallikrein Inhibitor drug class is projected to reach $600.0 Million by 2035.

Author

Author

Nidhi Mandole

Senior Research Analyst

She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Co-Author

Garvit Vyas

Vice President - Operations

Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.

Get In Touch

Leave a Comment